The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Factors associated with axillary conversion after neoadjuvant chemotherapy in initially node positive breast cancer patients: A transSENTINA analysis.
 
Hans-Christian Kolberg
Stock and Other Ownership Interests - Phaon Scientific; Theraclion
Honoraria - Amgen; AstraZeneca; Carl Zeiss Meditec; Genomic Health; MSD Oncology; Novartis; Pfizer; Roche; SurgVision; Theraclion; Theramex
Consulting or Advisory Role - Amgen; SurgVision
Travel, Accommodations, Expenses - Amgen; Carl Zeiss Meditec; Daiichi Sankyo; Genomic Health; LIV Pharma; Novartis; Pfizer; Roche; Tesaro
 
Thorsten Kühn
No Relationships to Disclose
 
Maja Krajewska
No Relationships to Disclose
 
Ingo Bauerfeind
No Relationships to Disclose
 
Tanja N. Fehm
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; MSD Oncology; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
 
Barbara Fleige
No Relationships to Disclose
 
Gisela Helms
No Relationships to Disclose
 
Annette Lebeau
Research Funding - Roche; Roche
Travel, Accommodations, Expenses - Novartis; Roche
 
Annette Staebler
No Relationships to Disclose
 
Sibylle Loibl
Honoraria - Chugai Pharma
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Cepheid (Inst); Daiichi Sankyo (Inst); Immunomedics (Inst); Myriad Genetics (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Vifor Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending EP14153692.0 (Inst)
 
Michael Untch
Honoraria - Art tempi (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); MSD Oncology (Inst); Mundipharma (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Celgene (Inst); Lilly (Inst); MSD Oncology (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer (Inst); Roche Pharma AG (Inst)
 
Cornelia Kolberg-Liedtke
Stock and Other Ownership Interests - Phaon Scientific (I); Theraclion (I)
Honoraria - Amgen; Amgen (I); AstraZeneca; AstraZeneca (I); Carl Zeiss Meditec (I); Celgene; Genomic Health (I); GlaxoSmithKline (I); HEXAL; Janssen-Cilag (I); Lilly; LIV Pharma (I); Novartis; Novartis (I); Pfizer; Pfizer (I); RIEMSER (I); Roche; Roche (I); SonoScape; Teva (I); Teva (I); Theraclion (I)
Consulting or Advisory Role - Amgen (I); Carl Zeiss Meditec (I); Celgene; Novartis; Novartis (I); Onkowissen (I); Pfizer; Pfizer (I); Phaon Scientific; Roche; SurgVision (I)
Research Funding - Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Amgen (I); Carl Zeiss Meditec (I); Daiichi Sankyo; Daiichi Sankyo (I); LIV Pharma (I); Novartis; Novartis (I); Pfizer (I); Roche